We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Read MoreHide Full Article
Key Takeaways
Sanofi will acquire BPMC for up to $9.5B, including a 27% premium and CVRs tied to BLU-808 milestones.
The deal adds Ayvakit, which saw Q1 2025 sales of $149.4M and is projected to hit $2B by 2030.
SNY aims to reduce Dupixent reliance by expanding its immunology portfolio through acquisitions.
Sanofi (SNY - Free Report) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC - Free Report) for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are up 26% today. Subject to the fulfillment of certain customary closing conditions, Sanofi currently expects to complete the acquisition in the third quarter of 2025.
The impending acquisition will add Blueprint Medicines’ only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi’s commercial portfolio, expanding the latter’s presence in rare immunological diseases.Ayvakit was initially approved in the United States and the EU to treat gastrointestinal stromal tumors. Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis (SM).
Year to date, shares of Sanofi have gained 2.4% against the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
The acquisition will also add Blueprint Medicines’ innovative pipeline candidates to Sanofi’s early-stage immunology pipeline.
In the first quarter of 2025, product revenues from Ayvakit sales totaled $149.4 million, representing a 61% year-over-year increase, driven by new patient starts, low discontinuation rates, and a high compliance rate. The company expects to achieve Ayvakit sales of $2 billion by 2030.
Year to date, BPMC shares have gained 16.2% against the industry’s 3.8% decline.
Image Source: Zacks Investment Research
SNY/BPMC Deal’s Financial Considerations in Detail
Under the terms of the acquisition, Sanofi will pay $129 per share in cash upon closing the deal, indicating a premium of approximately 27% over the closing price of BPMC on Friday, resulting in an equity value of approximately $9.1 billion.
In addition, Blueprint Medicines shareholders will receive a non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on the achievement of future development and regulatory milestones for BLU-808. Including these potential CVR payments, the total equity value of the transaction, approximately amounts to a whopping $9.5 billion.
Blueprint Medicines Corporation Price and Consensus
Sanofi clarified that the BPMC acquisition will not materially impact its financial guidance for 2025.
What's Sanofi’s Intent Behind the Deal?
Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib. Through this deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Last month, Sanofi completed the acquisition of California-based Dren Bio’s investigational bispecific antibody, DR-0201, for a financial consideration of up to $1.9 billion. The candidate is being evaluated in two ongoing early-stage studies — B-cell non-Hodgkin lymphoma and autoimmune diseases.
The potential success in the development of the above candidates will help the company narrow its dependence on the blockbuster immunology drug Dupixent, which is marketed in collaboration with Regeneron. This drug is currently a key top-line driver for both SNY and REGN. In first-quarter 2025, Sanofi recorded €3.48 billion from Dupixent product sales, indicating 20% year-over-year growth. The reported Dupixent sales figure accounted for about a third of the company’s total first-quarter revenues.
SNY/BPMC Zacks Rank and Stocks to Consider
Sanofi and Blueprint Medicines currently carry a Zacks Rank #3 (Hold) each.
In the past 60 days, estimates for Bayer’s earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 44.9%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
In the past 60 days, estimates for Amarin’s loss per share for 2025 have narrowed from $5.33 to $2.78. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.04. Year to date, shares of AMRN have gained 19.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines
Key Takeaways
Sanofi (SNY - Free Report) announced that it has entered into a definitive agreement to acquire Blueprint Medicines (BPMC - Free Report) for a total deal value of up to $9.5 billion. Following the announcement, shares of BPMC are up 26% today. Subject to the fulfillment of certain customary closing conditions, Sanofi currently expects to complete the acquisition in the third quarter of 2025.
The impending acquisition will add Blueprint Medicines’ only marketed product, Ayvakit (avapritinib), an inhibitor of KIT and PDGFRA proteins, to Sanofi’s commercial portfolio, expanding the latter’s presence in rare immunological diseases.Ayvakit was initially approved in the United States and the EU to treat gastrointestinal stromal tumors. Later, the drug’s label was expanded by respective regulatory authorities in both geographies to treat advanced and indolent systemic mastocytosis (SM).
Year to date, shares of Sanofi have gained 2.4% against the industry’s decline of 3.6%.
Image Source: Zacks Investment Research
The acquisition will also add Blueprint Medicines’ innovative pipeline candidates to Sanofi’s early-stage immunology pipeline.
In the first quarter of 2025, product revenues from Ayvakit sales totaled $149.4 million, representing a 61% year-over-year increase, driven by new patient starts, low discontinuation rates, and a high compliance rate. The company expects to achieve Ayvakit sales of $2 billion by 2030.
Year to date, BPMC shares have gained 16.2% against the industry’s 3.8% decline.
Image Source: Zacks Investment Research
SNY/BPMC Deal’s Financial Considerations in Detail
Under the terms of the acquisition, Sanofi will pay $129 per share in cash upon closing the deal, indicating a premium of approximately 27% over the closing price of BPMC on Friday, resulting in an equity value of approximately $9.1 billion.
In addition, Blueprint Medicines shareholders will receive a non-tradeable contingent value right (CVR), entitling them to two potential milestone payments of $2 and $4 per CVR, contingent on the achievement of future development and regulatory milestones for BLU-808. Including these potential CVR payments, the total equity value of the transaction, approximately amounts to a whopping $9.5 billion.
Blueprint Medicines Corporation Price and Consensus
Blueprint Medicines Corporation price-consensus-chart | Blueprint Medicines Corporation Quote
Sanofi clarified that the BPMC acquisition will not materially impact its financial guidance for 2025.
What's Sanofi’s Intent Behind the Deal?
Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib. Through this deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Last month, Sanofi completed the acquisition of California-based Dren Bio’s investigational bispecific antibody, DR-0201, for a financial consideration of up to $1.9 billion. The candidate is being evaluated in two ongoing early-stage studies — B-cell non-Hodgkin lymphoma and autoimmune diseases.
Sanofi Price and Consensus
Sanofi price-consensus-chart | Sanofi Quote
The potential success in the development of the above candidates will help the company narrow its dependence on the blockbuster immunology drug Dupixent, which is marketed in collaboration with Regeneron. This drug is currently a key top-line driver for both SNY and REGN. In first-quarter 2025, Sanofi recorded €3.48 billion from Dupixent product sales, indicating 20% year-over-year growth. The reported Dupixent sales figure accounted for about a third of the company’s total first-quarter revenues.
SNY/BPMC Zacks Rank and Stocks to Consider
Sanofi and Blueprint Medicines currently carry a Zacks Rank #3 (Hold) each.
Some better-ranked stocks in the biotech sector are Bayer (BAYRY - Free Report) and Amarin (AMRN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Bayer’s earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 44.9%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
In the past 60 days, estimates for Amarin’s loss per share for 2025 have narrowed from $5.33 to $2.78. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.04. Year to date, shares of AMRN have gained 19.5%.
AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.